Partial Loss of the Glutamate Transporter GLT-1 Alters Brain Akt and Insulin Signaling in a Mouse Model of Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 45, Issue 2, 2015, Pages 509-520

  Meeker, Kole D ^a,b   Meabon, James S ^a,b   Cook, David G ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Amyloid ; EAAT2; excitotoxicity; GLT1; metabolism; SLC1A2

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULINASE; PROTEIN KINASE B; SERINE; TYROSINE; VESICULAR GLUTAMATE TRANSPORTER 1; AMYLOID PRECURSOR PROTEIN; EXCITATORY AMINO ACID TRANSPORTER 2; ONCOPROTEIN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HETEROZYGOSITY; HUMAN; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; AGE; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; GENETICS; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID TRANSPORTER 2; HUMANS; INSULIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; ONCOGENE PROTEIN V-AKT; PRESENILIN-1; SIGNAL TRANSDUCTION;

EID: 84925378535     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142304     Document Type: Article

References (75)

1. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699-1702.
2. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65, 1-105.
3. Jarzylo LA, Man HY (2012) Parasynaptic NMDA receptor signaling couples neuronal glutamate transporter function to AMPA receptor synaptic distribution and stability. J Neurosci 32, 2552-2563.
4. Haugeto O, Ullensvang K, Levy LM, Chaudhry FA, Honore T, Nielsen M, Lehre KP, Danbolt NC (1996) Brain glutamate transporter proteins form homomultimers. J Biol Chem 271, 27715-27722.
5. Lehre KP, Danbolt NC (1998) The number of glutamate transporter subtype molecules at glutamatergic synapses: Chemical and stereological quantification in young adult rat brain. J Neurosci 18, 8751-8757.
6. Huang YH, Dykes-Hoberg M, Tanaka K, Rothstein JD, Bergles DE (2004) Climbing fiber activation of EAAT4 transporters and kainate receptors in cerebellar Purkinje cells. J Neurosci 24, 103-111.
7. Peghini P, Janzen J, Stoffel W (1997) Glutamate transporter EAAC-1-deficient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. EMBO J 16, 3822-3832.
8. Watase K, Hashimoto K, Kano M, Yamada K, Watanabe M, Inoue Y, Okuyama S, Sakagawa T, Ogawa S, Kawashima N, Hori S, Takimoto M, Wada K, Tanaka K (1998) Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. Eur J Neurosci 10, 976-988.
9. Aoyama K, Suh SW, Hamby AM, Liu J, Chan WY, Chen Y, SwansonRA(2006) Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci 9, 119-126.
10. Arzberger T, Krampfl K, Leimgruber S, Weindl A (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J Neuropathol Exp Neurol 56, 440-454.
11. Hassel B, Tessler S, Faull RL, Emson PC (2008) Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 33, 232-237.
12. van Landeghem FK, Weiss T, Oehmichen M, von Deimling A (2006) Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J Neurotrauma 23, 1518-1528.
13. Rothstein JD, Martin LJ, Kuncl RW (1992) Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326, 1464-1468.
14. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW(1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38, 73-84.
15. Maragakis NJ, Dykes-HobergM, Rothstein JD (2004) Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol 55, 469-477.
16. Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, Montine TJ, Kaye JA, Quinn JF, Silbert L, Erten- Lyons D, Leverenz JB, Bird TD, Pow DV, Tanaka K, Watson GS, Cook DG (2010) Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol 69, 667-676.
17. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis 11, 97-116.
18. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40, 759-766.
19. Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H, 3rd, Kraner SD, Norris CM (2009) Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 29, 12957-12969.
20. Mookherjee P, Green PS, Watson GS, Marques MA, Tanaka K, Meeker KD, Meabon JS, Li N, Zhu P, Olson VG, Cook DG (2011) GLT-1 loss accelerates cognitive deficit onset in an Alzheimer's disease animal model. J Alzheimers Dis 26, 447-455.
21. Scimemi A, Meabon JS, woltjer RL, Sullivan JM, Diamond JS, Cook DG (2013) Amyloid-beta 1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci 33, 5312-5318.
22. Herman MA, Jahr CE (2007) Extracellular glutamate concentration in hippocampal slice. J Neurosci 27, 9736-9741.
23. Voutsinos-Porche B, Bonvento G, Tanaka K, Steiner P, Welker E, Chatton JY, Magistretti PJ, Pellerin L (2003) Glial glutamate transporters mediate a functional metabolic crosstalk between neurons and astrocytes in the mouse developing cortex. Neuron 37, 275-286.
24. Herard AS, Dubois A, Escartin C, Tanaka K, Delzescaux T, Hantraye P, Bonvento G(2005) Decreased metabolic response to visual stimulation in the superior colliculus of mice lacking the glial glutamate transporter GLT-1. Eur J Neurosci 22, 1807-1811.
25. Ji YF, Xu SM, Zhu J, Wang XX, Shen Y (2011) Insulin increases glutamate transporter GLT1 in cultured astrocytes. Biochem Biophys Res Commun 405, 691-696.
26. Wu X, Kihara T, Akaike A, Niidome T, Sugimoto H (2010) PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. Biochem Biophys Res Commun 393, 514-518.
27. Li LB, Toan SV, Zelenaia O, Watson DJ, Wolfe JH, Rothstein JD, Robinson MB (2006) Regulation of astrocytic glutamate transporter expression by Akt: Evidence for a selective transcriptional effect on the GLT-1/EAAT2 subtype. J Neurochem 97, 759-771.
28. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 93, 105-117.
29. Pei JJ, Khatoon S, An WL, Nordlinder M, Tanaka T, Braak H, Tsujio I, Takeda M, Alafuzoff I, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K (2003) Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol 105, 381-392.
30. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF (2004) Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 15, 955-959.
31. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31, 224-243.
32. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
33. Cholerton B, Baker LD, Craft S (2013) Insulin, cognition, and dementia. Eur J Pharmacol 719, 170-179.
34. de la Monte SM, Tong M(2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 88, 548-559.
35. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-260.
36. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-904.
37. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta- protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167.
38. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162, 313-319.
39. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159-170.
40. Bennett RG, Duckworth WC, Hamel FG (2000) Degradation of amylin by insulin-degrading enzyme. J Biol Chem 275, 36621-36625.
41. Winer BJ, Brown DR, Michels KM (1991) Statistical Principles in Experimental Design, McGraw-Hill, Inc.
42. Field A (2005) Discovering Statistics Using SPSS, Sage Publications, London.
43. Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Condorelli G, Sadoshima J, Trimarco B (2005) Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res 96, 180-188.
44. Tian R (2005) Another role for the celebrity: Akt and insulin resistance. Circ Res 96, 139-140.
45. Zhao Z, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huber HE, Duggan ME, Lindsley CW (2008) Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg Med Chem Lett 18, 49-53.
46. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 7, 85-96.
47. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesityinduced insulin resistance. Science 271, 665-668.
48. Boura-Halfon S, Zick Y (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 296, E581-E591.
49. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB (2001) A phosphatidylinositol 3- kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci U S A 98, 4640-4645.
50. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 95, 1432-1437.
51. Magnuson B, Ekim B, Fingar DC (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441, 1-21.
52. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18, 240-252.
53. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM(2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 28, 824-830.
54. Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JP Jr., Pyrek JS, Estus S, Hersh LB(2000) Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 20, 8745-8749.
55. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Abeta peptide: The many roads to perdition. Neuron 43, 605-608.
56. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89, 807-811.
57. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
58. Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, Frangione B (2004) Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 279, 45897-45908.
59. Marques MA, Kulstad JJ, Savard CE, Green PS, Lee SP, Craft S, Watson GS, Cook DG (2009) Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system. J Alzheimers Dis 16, 325-329.
60. Duckworth WC, Bennett RG, Hamel FG(1998) Insulin degradation: Progress and potential. Endocr Rev 19, 608-624.
61. Berger UV, Hediger MA (2006) Distribution of the glutamate transporters GLT-1 (SLC1A2) and GLAST (SLC1A3) in peripheral organs. Anat Embryol (Berl) 211, 595-606.
62. Raichle ME, Gusnard DA (2002) Appraising the brain's energy budget. Proc Natl Acad Sci U S A 99, 10237-10239.
63. Jackson JG, O'Donnell JC, Takano H, Coulter DA, Robinson MB (2014) Neuronal activity and glutamate uptake decrease mitochondrial mobility in astrocytes and position mitochondria near glutamate transporters. J Neurosci 34, 1613-1624.
64. Sesti G (2006) Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab 20, 665-679.
65. Meabon JS, Lee A, Meeker KD, Bekris LM, Fujimura RK, Yu CE, Watson GS, Pow DV, Sweet IR, Cook DG (2012) Differential expression of the glutamate transporter GLT-1 in pancreas. J Histochem Cytochem 60, 139-151.
66. Zhou Y, Waanders LF, Holmseth S, Guo C, Berger UV, Li Y, Lehre AC, Lehre KP, Danbolt NC (2014) Proteome analysis and conditional deletion of the EAAT2 glutamate transporter provide evidence against a role ofEAAT2 in pancreatic insulin secretion in mice. J Biol Chem 289, 1329-1344.
67. Diamond JS, Jahr CE (2000) Synaptically released glutamate does not overwhelm transporters on hippocampal astrocytes during high-frequency stimulation. J Neurophysiol 83, 2835-2843.
68. Diamond JS, Jahr CE (1997) Transporters buffer synaptically released glutamate on a submillisecond time scale. J Neurosci 17, 4672-4687.
69. Tsvetkov E, Shin RM, Bolshakov VY (2004) Glutamate uptake determines pathway specificity of long-term potentiation in the neural circuitry of fear conditioning. Neuron 41, 139-151.
70. Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA (2011) Deletion of insulin-degrading enzyme elicits Brain Akt in AD Mouse antipodal, age-dependent effects on glucose and insulin tolerance. PLoS One 6, e20818.
71. Leissring MA, FarrisW, Chang AY, Walsh DM, WuX, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of betaamyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
72. Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers WH, Kitajewski J, Kahn A, Perret C (2002) New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21, 8293-8301.
73. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31, 151-173.
74. Hone E, Martins IJ, Fonte J, Martins RN (2003) Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 5, 1-8.
75. Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, Yabuki C, Terasaki T (2006) Major involvement of lowdensity lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 23, 1407-1416.